Hyderabad: Forests, Environment and Endowments Minister Konda Surekha on Wednesday released the official poster of Telangana ...

A PDF of the poster presented at IAPRD 2025 30 th World Congress on Parkinson's Disease and Related Disorders is available on ...

Session: Oral Poster Presentation – Guided Poster TourSession ... is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation.

Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant ...

Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Gain Therapeutics is presenting their lead drug candidate, GT-02287, for Parkinson's disease at the IAPRD conference. When is the oral poster presentation scheduled? The oral poster presentation ...

Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects ...

Social media users slammed the stranger's behavior, with one saying: "Anyone around him was reflecting on what an immature jerk he was." ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...